Travere Therapeutics Stock (NASDAQ: TVTX) stock price, news, charts, stock research, profile.
Open | $5.780 |
Close | - |
Volume / Avg. | 344.541K / 1.174M |
Day Range | 5.415 - 5.780 |
52 Wk Range | 5.250 - 22.750 |
Market Cap | $461.570M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 24 |
Short Interest | 15.67% |
Days to Cover | 10.73 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Travere Therapeutics (NASDAQ: TVTX) through any online brokerage.
Other companies in Travere Therapeutics’s space includes: Humacyte (NASDAQ:HUMA), KalVista Pharma (NASDAQ:KALV), Voyager Therapeutics (NASDAQ:VYGR), Larimar Therapeutics (NASDAQ:LRMR) and Replimune Group (NASDAQ:REPL).
The latest price target for Travere Therapeutics (NASDAQ: TVTX) was reported by Wedbush on Wednesday, April 17, 2024. The analyst firm set a price target for 13.00 expecting TVTX to rise to within 12 months (a possible 114.36% upside). 35 analyst firms have reported ratings in the last year.
The stock price for Travere Therapeutics (NASDAQ: TVTX) is $6.0646 last updated Today at April 24, 2024 at 8:25 AM EDT.
There are no upcoming dividends for Travere Therapeutics.
Travere Therapeutics’s Q1 earnings are confirmed for Monday, May 6, 2024.
There is no upcoming split for Travere Therapeutics.
Travere Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.